Harbour BioMed follows cancer drug deals with a hefty $85M Series B backed by Singapore's GIC
Riding on the momentum of two licensing deals, Harbour BioMed now has $85 million to advance its freshly beefed up pipeline.
GIC — Singapore’s sovereign wealth fund — led the Series B, leading a syndicate that includes China Life Private Equity Investment and Vertex Ventures as well as Series A investors AdvanTech and Legend Capital.
Founder and CEO Jingsong Wang calls the round a “strong vote of confidence” for the Chinese biotech’s three-pronged strategy built around its foundational human transgenic antibody technology, dubbed Harbour Mice: out-licensing its tech, in-licensing assets to develop on the platform and discovering new ones in-house.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.